ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP lessened its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 11.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 105,459 shares of the biotechnology company's stock after selling 13,834 shares during the period. Wellington Management Group LLP's holdings in ADMA Biologics were worth $1,809,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. HighTower Advisors LLC increased its stake in ADMA Biologics by 41.1% during the 3rd quarter. HighTower Advisors LLC now owns 87,471 shares of the biotechnology company's stock worth $1,748,000 after buying an additional 25,492 shares in the last quarter. National Bank of Canada FI acquired a new stake in shares of ADMA Biologics in the third quarter worth approximately $35,000. Barclays PLC increased its position in shares of ADMA Biologics by 192.2% during the third quarter. Barclays PLC now owns 528,629 shares of the biotechnology company's stock worth $10,567,000 after purchasing an additional 347,692 shares in the last quarter. Geode Capital Management LLC raised its stake in ADMA Biologics by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 5,381,985 shares of the biotechnology company's stock valued at $107,606,000 after purchasing an additional 137,989 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky purchased a new position in ADMA Biologics in the 3rd quarter valued at $1,047,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Trading Up 0.4 %

ADMA Biologics stock traded up $0.08 during trading on Friday, reaching $21.31. 2,965,421 shares of the company were exchanged, compared to its average volume of 3,616,169. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The stock's 50 day simple moving average is $18.26 and its two-hundred day simple moving average is $18.23. The company has a market capitalization of $5.04 billion, a P/E ratio of 76.11 and a beta of 0.53. ADMA Biologics, Inc. has a 52-week low of $6.10 and a 52-week high of $23.64.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 target price on shares of ADMA Biologics in a research report on Tuesday, March 4th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.